Effects of metformin dose on cancer risk reduction in patients with type 2 diabetes mellitus: A 6-year follow-up study

Pharmacotherapy

Volumn 34, Issue 1, 2014, Pages 36-45

  Lin, Hsiu Chen ^a,b   Kachingwe, Baxter H ^c   Lin, Hsiu Li ^c,d   Cheng, Hui Wen ^c   Uang, Yow Shieng ^c   Wang, Li Hsuan ^b,c  

^a Department of Pediatrics School of Medicine College of Medicine ^*  (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d General Cathay Hospital   (Taiwan)

Author keywords

Cancer; Dose effect; Metformin; Risk; Type 2 diabetes

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CANCER RISK; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

CANCER; DOSE EFFECT; METFORMIN; RISK; TYPE 2 DIABETES;

ADULT; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; METFORMIN; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898048917     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1334     Document Type: Article

References (45)

1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32: 193-203.
2. Sahra IB, Le Marchand-Brustel Y, Tanti J-F, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9: 1092-9.
3. Evans JMM, Donnelly LA, Esmile-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetes patients. BMJ 2005;330: 1304-5.
4. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33: 1674-85.
5. Helminki K, Li X, Sundquist J, Sandquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist 2010;15: 548-55.
6. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer 2009;16: 1103-23.
7. Suh S, Kim KW. Diabetes and cancer: is diabetes causally related to cancer? Diabetes Metab J 2011;35: 193-8.
8. Cannata D, Fierz Y, Vijayakumar A, LeRoith D. Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med 2010;77: 197-213.
9. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49: 2819-23.
10. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52: 1699-708.
11. Monami M, Colombi C, Balzi D, et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011;34: 129-31.
12. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009;46: 279-84.
13. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25: 1476-81.
14. Dai Y, Wang WH. Peroxisome proliferator-activated receptor c and colorectal cancer. World J Gastrointest Oncol 2010;2: 159-64.
15. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and the cancer mortality in type 2 diabetes assessing effects of time-varying exposure. Diabetologia 2010;53: 1631-7.
16. Currie CJ, Poole CD, Gale EAM. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52: 1766-77.
17. Lipscombe LL, Goodwin PJ, Zinman B, Mclaughlin JR, Hux JE. Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 2006;98: 303-9.
18. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Rev Cancer 2008;8: 915-28.
19. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2008;8: 88-96.
20. Zhuang Y, Miskimins WK. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, down-regulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008;3: 18-28.
21. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with antidiabetic drug metformin selectively impairs p53-deficient tumour cell growth. Cancer Res 2007;67: 6745-53.
22. Ben Sahra IB, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoural effect in in-vitro and in-vivo through a decrease of cyclin D1 level. Oncogene 2008;27: 3576-86.
23. McFarland MS, Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy 2010;30: 1159-78.
24. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009;20: 1617-22.
25. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and complete pathologic response to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27: 3297-302.
26. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect the risk of pancreatic cancer. Gastroenterology 2009;137: 482-8.
27. Bo S, Ciccone G, Rosato R, et al. Cancer mortality reduction and metformin. Diabetes Obes Metab 2012;14: 23-9.
28. Lee MS, Hsu CC, Wahlqvist LM, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11: 20. doi: 10.1186/1471-2407-11.
29. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32: 1620-5.
30. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66: 10269-73.
31. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69: 7507-11.
32. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 2010;59: 686-93.
33. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010;3: 1066-76.
34. Jalving MG, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer 2010;46: 2369-80.
35. Engelman JA, Cantley LC. Chemoprevention meets glucose control. Cancer Prev Res (Phila) 2010;3: 1049-52.
36. Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol 2011;164: 68-82.
37. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr 2008;2: 47-57.
38. Chowdhury TA. Diabetes and cancer. QJM 2010;103: 905-15.
39. Okumura T. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol 2010;45: 1097-102.
40. Raji A, Seely EW, Arky RA, Simonson DC. Body fat distribution and insulin resistance in healthy Asian Indians and Caucasians. J Clin Endocrinol Metab 2001;86: 5366-71.
41. Weber MB, Oza-Frank R, Staimez LR, Ali MK, Narayan KM. Type 2 diabetes in Asians: prevalence, risk factors, and effectiveness of behavioral intervention at individual and population levels. Annu Rev Nutr 2012;32: 417-39.
42. Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375: 408-18.
43. Yang X, So WY, Ma RC, et al. Use of thiazolidinedione and cancer risk in type 2 diabetes: the Hong Kong diabetes registry. Diabetes Res Clin Pract 2012;97:e13-7.
44. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50: 81-98.
45. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 2005;104: 157-63.